APOBEC3B-Mediated Cytidine Deamination Is Required for Estrogen Receptor Action in Breast Cancer

Cell Reports

Volumn 13, Issue 1, 2015, Pages 108-121

  Periyasamy, Manikandan ^a   Patel, Hetal ^a   Lai, Chun Fui ^a   Nguyen, Van T M ^a   Nevedomskaya, Ekaterina ^b   Harrod, Alison ^a   Russell, Roslin ^c   Remenyi, Judit ^d   Ochocka, Anna Maria ^a   Thomas, Ross S ^a   Fuller Pace, Frances ^d   Gyorffy, Balázs ^e   Caldas, Carlos ^c   Navaratnam, Naveenan ^f   Carroll, Jason S ^c   Zwart, Wilbert ^b   Coombes, R Charles ^a   Magnani, Luca ^a   Buluwela, Laki ^a   Ali, Simak ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^d UNIVERSITY OF DUNDEE   (United Kingdom)

^e SEMMELWEIS UNIVERSITY   (Hungary)

^f HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOBEC3B PROTEIN; CYTIDINE; CYTOSINE; ESTROGEN RECEPTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG; URIDINE; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; DNA; ESTROGEN RECEPTOR ALPHA; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN BINDING; SMALL INTERFERING RNA; TFF1 PROTEIN, HUMAN; TREFOIL FACTOR 1; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DEAMINATION; DNA END JOINING REPAIR; DNA STRAND BREAKAGE; EXCISION REPAIR; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; ANTAGONISTS AND INHIBITORS; BINDING SITE; BREAST TUMOR; CELL PROLIFERATION; DNA DAMAGE; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE;

BINDING SITES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYTIDINE; CYTIDINE DEAMINASE; DEAMINATION; DNA; DNA DAMAGE; DNA END-JOINING REPAIR; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MINOR HISTOCOMPATIBILITY ANTIGENS; PROGNOSIS; PROTEIN BINDING; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREFOIL FACTOR-1; TUMOR SUPPRESSOR PROTEINS;

EID: 84943237337     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.08.066     Document Type: Article

References (65)

1. Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., Bignell G.R., Bolli N., Borg A., Børresen-Dale A.L., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421. Australian Pancreatic Cancer Genome Initiative, ICGC Breast Cancer ConsortiumICGC Breast Cancer Consortium, ICGC MMML-Seq ConsortiumICGC MMML-Seq Consortium, ICGC PedBrainICGC PedBrain.
2. Ali S., Coombes R.C. Endocrine-responsive breast cancer and strategies for combating resistance. Nat. Rev. Cancer 2002, 2:101-112.
3. Anzick S.L., Kononen J., Walker R.L., Azorsa D.O., Tanner M.M., Guan X.Y., Sauter G., Kallioniemi O.P., Trent J.M., Meltzer P.S. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 1997, 277:965-968.
4. Bhat-Nakshatri P., Campbell R.A., Patel N.M., Newton T.R., King A.J., Marshall M.S., Ali S., Nakshatri H. Tumour necrosis factor and PI3-kinase control oestrogen receptor alpha protein level and its transrepression function. Br. J. Cancer 2004, 90:853-859.
5. Bhutani N., Burns D.M., Blau H.M. DNA demethylation dynamics. Cell 2011, 146:866-872.
6. Bogerd H.P., Wiegand H.L., Doehle B.P., Cullen B.R. The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains. Virology 2007, 364:486-493.
7. Burns M.B., Lackey L., Carpenter M.A., Rathore A., Land A.M., Leonard B., Refsland E.W., Kotandeniya D., Tretyakova N., Nikas J.B., et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013, 494:366-370.
8. Burns M.B., Temiz N.A., Harris R.S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat. Genet. 2013, 45:977-983.
9. Compe E., Egly J.M. TFIIH: when transcription met DNA repair. Nat. Rev. Mol. Cell Biol. 2012, 13:343-354.
10. Conticello S.G. The AID/APOBEC family of nucleic acid mutators. Genome Biol. 2008, 9:229.
11. Curtis C., Shah S.P., Chin S.F., Turashvili G., Rueda O.M., Dunning M.J., Speed D., Lynch A.G., Samarajiwa S., Yuan Y., et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012, 486:346-352. METABRIC Group.
12. Dahlman-Wright K., Cavailles V., Fuqua S.A., Jordan V.C., Katzenellenbogen J.A., Korach K.S., Maggi A., Muramatsu M., Parker M.G., Gustafsson J.A. International Union of Pharmacology. LXIV. Estrogen receptors. Pharmacol. Rev. 2006, 58:773-781.
13. de Bruin E.C., McGranahan N., Mitter R., Salm M., Wedge D.C., Yates L., Jamal-Hanjani M., Shafi S., Murugaesu N., Rowan A.J., et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014, 346:251-256.
14. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., Viale G., Delorenzi M., Zhang Y., d'Assignies M.S., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214. TRANSBIG Consortium.
15. An integrated encyclopedia of DNA elements in the human genome. Nature 2012, 489:57-74. ENCODE Project Consortium.
16. Fong Y.W., Cattoglio C., Tjian R. The intertwined roles of transcription and repair proteins. Mol. Cell 2013, 52:291-302.
17. Guedj M., Marisa L., de Reynies A., Orsetti B., Schiappa R., Bibeau F., MacGrogan G., Lerebours F., Finetti P., Longy M., et al. A refined molecular taxonomy of breast cancer. Oncogene 2012, 31:1196-1206.
18. Hah N., Murakami S., Nagari A., Danko C.G., Kraus W.L. Enhancer transcripts mark active estrogen receptor binding sites. Genome Res. 2013, 23:1210-1223.
19. Hnisz D., Abraham B.J., Lee T.I., Lau A., Saint-André V., Sigova A.A., Hoke H.A., Young R.A. Super-enhancers in the control of cell identity and disease. Cell 2013, 155:934-947.
20. Iacovoni J.S., Caron P., Lassadi I., Nicolas E., Massip L., Trouche D., Legube G. High-resolution profiling of gammaH2AX around DNA double strand breaks in the mammalian genome. EMBO J. 2010, 29:1446-1457.
21. Iurlaro M., Ficz G., Oxley D., Raiber E.A., Bachman M., Booth M.J., Andrews S., Balasubramanian S., Reik W. A screen for hydroxymethylcytosine and formylcytosine binding proteins suggests functions in transcription and chromatin regulation. Genome Biol. 2013, 14:R119.
22. Ju B.G., Lunyak V.V., Perissi V., Garcia-Bassets I., Rose D.W., Glass C.K., Rosenfeld M.G. A topoisomerase IIbeta-mediated dsDNA break required for regulated transcription. Science 2006, 312:1798-1802.
23. Kamileri I., Karakasilioti I., Garinis G.A. Nucleotide excision repair: new tricks with old bricks. Trends Genet. 2012, 28:566-573.
24. Khurana S., Kruhlak M.J., Kim J., Tran A.D., Liu J., Nyswaner K., Shi L., Jailwala P., Sung M.H., Hakim O., Oberdoerffer P. A macrohistone variant links dynamic chromatin compaction to BRCA1-dependent genome maintenance. Cell Rep. 2014, 8:1049-1062.
25. Komatsu A., Nagasaki K., Fujimori M., Amano J., Miki Y. Identification of novel deletion polymorphisms in breast cancer. Int. J. Oncol. 2008, 33:261-270.
26. Kotnis A., Du L., Liu C., Popov S.W., Pan-Hammarström Q. Non-homologous end joining in class switch recombination: the beginning of the end. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2009, 364:653-665.
27. Kulaeva O.I., Nizovtseva E.V., Polikanov Y.S., Ulianov S.V., Studitsky V.M. Distant activation of transcription: mechanisms of enhancer action. Mol. Cell. Biol. 2012, 32:4892-4897.
28. Lai C.F., Flach K.D., Alexi X., Fox S.P., Ottaviani S., Thiruchelvam P.T., Kyle F.J., Thomas R.S., Launchbury R., Hua H., et al. Co-regulated gene expression by oestrogen receptor α and liver receptor homolog-1 is a feature of the oestrogen response in breast cancer cells. Nucleic Acids Res. 2013, 41:10228-10240.
29. Landry S., Narvaiza I., Linfesty D.C., Weitzman M.D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep. 2011, 12:444-450.
30. Lee H.S., Park J.H., Kim S.J., Kwon S.J., Kwon J. A cooperative activation loop among SWI/SNF, gamma-H2AX and H3 acetylation for DNA double-strand break repair. EMBO J. 2010, 29:1434-1445.
31. Leonard B., Hart S.N., Burns M.B., Carpenter M.A., Temiz N.A., Rathore A., Vogel R.I., Nikas J.B., Law E.K., Brown W.L., et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 2013, 73:7222-7231.
32. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., Zhang J., Rose D.W., Fu X.D., Glass C.K., Rosenfeld M.G. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009, 139:1069-1083.
33. Lopez-Garcia J., Periyasamy M., Thomas R.S., Christian M., Leao M., Jat P., Kindle K.B., Heery D.M., Parker M.G., Buluwela L., et al. ZNF366 is an estrogen receptor corepressor that acts through CtBP and histone deacetylases. Nucleic Acids Res. 2006, 34:6126-6136.
34. Lucey M.J., Chen D., Lopez-Garcia J., Hart S.M., Phoenix F., Al-Jehani R., Alao J.P., White R., Kindle K.B., Losson R., et al. T:G mismatch-specific thymine-DNA glycosylase (TDG) as a coregulator of transcription interacts with SRC1 family members through a novel tyrosine repeat motif. Nucleic Acids Res. 2005, 33:6393-6404.
35. Ma J., Wang M. Interplay between DNA supercoiling and transcription elongation. Transcription 2014, 5:e28636.
36. Magnani L., Eeckhoute J., Lupien M. Pioneer factors: directing transcriptional regulators within the chromatin environment. Trends Genet. 2011, 27:465-474.
37. McClelland R.A., Gee J.M., Francis A.B., Robertson J.F., Blamey R.W., Wakeling A.E., Nicholson R.I. Short-term effects of pure anti-oestrogen ICI 182780 treatment on oestrogen receptor, epidermal growth factor receptor and transforming growth factor-alpha protein expression in human breast cancer. Eur. J. Cancer 1996, 32A:413-416.
38. Métivier R., Reid G., Gannon F. Transcription in four dimensions: nuclear receptor-directed initiation of gene expression. EMBO Rep. 2006, 7:161-167.
39. Miller L.D., Smeds J., George J., Vega V.B., Vergara L., Ploner A., Pawitan Y., Hall P., Klaar S., Liu E.T., Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc. Natl. Acad. Sci. USA 2005, 102:13550-13555.
40. Nabel C.S., Kohli R.M. Molecular biology. Demystifying DNA demethylation. Science 2011, 333:1229-1230.
41. Ngan S., Stronach E.A., Photiou A., Waxman J., Ali S., Buluwela L. Microarray coupled to quantitative RT-PCR analysis of androgen-regulated genes in human LNCaP prostate cancer cells. Oncogene 2009, 28:2051-2063.
42. Nik-Zainal S., Alexandrov L.B., Wedge D.C., Van Loo P., Greenman C.D., Raine K., Jones D., Hinton J., Marshall J., Stebbings L.A., et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012, 149:979-993. Breast Cancer Working Group of the International Cancer Genome Consortium.
43. Nik-Zainal S., Wedge D.C., Alexandrov L.B., Petljak M., Butler A.P., Bolli N., Davies H.R., Knappskog S., Martin S., Papaemmanuil E., et al. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer. Nat. Genet. 2014, 46:487-491.
44. Nowarski R., Wilner O.I., Cheshin O., Shahar O.D., Kenig E., Baraz L., Britan-Rosich E., Nagler A., Harris R.S., Goldberg M., et al. APOBEC3G enhances lymphoma cell radioresistance by promoting cytidine deaminase-dependent DNA repair. Blood 2012, 120:366-375.
45. O'Donnell A.J., Macleod K.G., Burns D.J., Smyth J.F., Langdon S.P. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen. Endocr. Relat. Cancer 2005, 12:851-866.
46. Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu. Rev. Med. 2011, 62:233-247.
47. Pankotai T., Bonhomme C., Chen D., Soutoglou E. DNAPKcs-dependent arrest of RNA polymerase II transcription in the presence of DNA breaks. Nat. Struct. Mol. Biol. 2012, 19:276-282.
48. Perillo B., Ombra M.N., Bertoni A., Cuozzo C., Sacchetti S., Sasso A., Chiariotti L., Malorni A., Abbondanza C., Avvedimento E.V. DNA oxidation as triggered by H3K9me2 demethylation drives estrogen-induced gene expression. Science 2008, 319:202-206.
49. Polak P., Lawrence M.S., Haugen E., Stoletzki N., Stojanov P., Thurman R.E., Garraway L.A., Mirkin S., Getz G., Stamatoyannopoulos J.A., Sunyaev S.R. Reduced local mutation density in regulatory DNA of cancer genomes is linked to DNA repair. Nat. Biotechnol. 2014, 32:71-75.
50. Puc J., Kozbial P., Li W., Tan Y., Liu Z., Suter T., Ohgi K.A., Zhang J., Aggarwal A.K., Rosenfeld M.G. Ligand-dependent enhancer activation regulated by topoisomerase-I activity. Cell 2015, 160:367-380.
51. Roberts S.A., Lawrence M.S., Klimczak L.J., Grimm S.A., Fargo D., Stojanov P., Kiezun A., Kryukov G.V., Carter S.L., Saksena G., et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat. Genet. 2013, 45:970-976.
52. Ross-Innes C.S., Stark R., Teschendorff A.E., Holmes K.A., Ali H.R., Dunning M.J., Brown G.D., Gojis O., Ellis I.O., Green A.R., et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature 2012, 481:389-393.
53. Sabatier R., Finetti P., Cervera N., Lambaudie E., Esterni B., Mamessier E., Tallet A., Chabannon C., Extra J.M., Jacquemier J., et al. A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res. Treat. 2011, 126:407-420.
54. Schmidt D., Wilson M.D., Spyrou C., Brown G.D., Hadfield J., Odom D.T. ChIP-seq: using high-throughput sequencing to discover protein-DNA interactions. Methods 2009, 48:240-248.
55. Shanbhag N.M., Rafalska-Metcalf I.U., Balane-Bolivar C., Janicki S.M., Greenberg R.A. ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell 2010, 141:970-981.
56. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 2006, 6:360-368.
57. Spruijt C.G., Gnerlich F., Smits A.H., Pfaffeneder T., Jansen P.W., Bauer C., Münzel M., Wagner M., Müller M., Khan F., et al. Dynamic readers for 5-(hydroxy)methylcytosine and its oxidized derivatives. Cell 2013, 152:1146-1159.
58. Stavnezer J. Complex regulation and function of activation-induced cytidine deaminase. Trends Immunol. 2011, 32:194-201.
59. Suspène R., Henry M., Guillot S., Wain-Hobson S., Vartanian J.P. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR. J. Gen. Virol. 2005, 86:125-129.
60. Taylor B.J., Nik-Zainal S., Wu Y.L., Stebbings L.A., Raine K., Campbell P.J., Rada C., Stratton M.R., Neuberger M.S. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2013, 2:e00534.
61. Tini M., Benecke A., Um S.J., Torchia J., Evans R.M., Chambon P. Association of CBP/p300 acetylase and thymine DNA glycosylase links DNA repair and transcription. Mol. Cell 2002, 9:265-277.
62. Wang Y., Klijn J.G., Zhang Y., Sieuwerts A.M., Look M.P., Yang F., Talantov D., Timmermans M., Meijer-van Gelder M.E., Yu J., et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
63. Welboren W.J., van Driel M.A., Janssen-Megens E.M., van Heeringen S.J., Sweep F.C., Span P.N., Stunnenberg H.G. ChIP-Seq of ERalpha and RNA polymerase II defines genes differentially responding to ligands. EMBO J. 2009, 28:1418-1428.
64. Zhang Y., Liu T., Meyer C.A., Eeckhoute J., Johnson D.S., Bernstein B.E., Nusbaum C., Myers R.M., Brown M., Li W., Liu X.S. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008, 9:R137.
65. Zhang Y., Sieuwerts A.M., McGreevy M., Casey G., Cufer T., Paradiso A., Harbeck N., Span P.N., Hicks D.G., Crowe J., et al. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res. Treat. 2009, 116:303-309.